Last reviewed · How we verify

Switch to nortriptyline — Competitive Intelligence Brief

Switch to nortriptyline (Switch to nortriptyline) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tricyclic antidepressant (TCA). Area: Psychiatry / Mental Health.

marketed Tricyclic antidepressant (TCA) Norepinephrine transporter (NET), serotonin transporter (SERT) Psychiatry / Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

Switch to nortriptyline (Switch to nortriptyline) — Centre for Addiction and Mental Health. Nortriptyline is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at neuronal synapses, increasing their availability in the central nervous system.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Switch to nortriptyline TARGET Switch to nortriptyline Centre for Addiction and Mental Health marketed Tricyclic antidepressant (TCA) Norepinephrine transporter (NET), serotonin transporter (SERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tricyclic antidepressant (TCA) class)

  1. Centre for Addiction and Mental Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Switch to nortriptyline — Competitive Intelligence Brief. https://druglandscape.com/ci/switch-to-nortriptyline. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: